Globally, these results indicate that the Irf1−/− mice respond to AOM/DSS treatment with an increase in epithelial proliferation compared to controls, as well as an increase in ISCs, and this, at a time (D26) preceding tumor emergence. The gene discussed is IRF1; the disease is neoplasm.